最近の記事
2021/10/31
Generation of a Transgenic Zebrafish Line for In Vivo Assessment of Hepatic Apoptosis
2021/08/19
2021/07/09
Establishment of a Quality Control Protocol for Zebrafish Developmental Toxicity Studies
2020/10/13
2020/05/28
A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis
2019/10/15
C3orf70 Is Involved in Neural and Neurobehavioral Development
2019/09/22
2019/07/17
Aging-associated microstructural deterioration of vertebra in zebrafish
2019/03/18
Zebrafish yolk sac microinjection of thalidomide for assessment of developmental toxicology
2019/02/18
Toxicological Evaluation of SiO2 Nanoparticles by Zebrafish Embryo Toxicity Test
HOME > Publication List English > 詳細
Patient-Derived Cancer Xenograft Zebrafish Model (PDXZ) for Drug Discovery Screening and Personalized Medicine
The U.S. National Cancer Institute has been using bank-derived cell lines for drug screening for many years, but due to the lack of clinical efficacy of this 2D cell culture drug screening (<5%), it was discontinued in 2016, and patient-derived xenograft mouse model (PDXM, >80% clinical drug efficacy predictive capacity) has been rapidly developed internationally.
However, the PDXM requires severe immunodeficient mice, and it takes about one year to obtain quantitative drug efficacy test results, and many issues remain, such as cost.
We developed novel zebrafish model for patient-derived xenograft (PDXZ), and demonstrated that PDXZ has high rate and speed of engraftment in normal zebrafish when the immune system is immature, requires less than 100 patient cancer cells for transplantation, and can be quantitatively analyzed in 2 days. We report on the construction of a drug efficacy screening system that can be quantitatively analyzed within a week.
関連ファイル
関連リンク
Department of Systems Pharmacology, Mie University Graduate School of Medicine
